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ABSTRACT 
Alzheimer's disease (AD) is the most common type of dementia worldwide. Since curative treatment has not been 
established for AD yet and due to heavy financial and psychological costs of patients’ care, special attention has 
been paid to preventive interventions such as physical activity. Evidence shows that physical activity has protective 
effects on cognitive function and memory in AD patients. Several pathologic factors are involved in AD-associated 
cognitive impairment some of which are preventable by physical activity. Also, various experimental and clinical 
studies are in progress to prove exercise role in the beta-amyloid (Aβ) pathology as a most prevailing hypothesis 
explaining AD pathogenesis. This study aims to review the role of physical activity in Aβ-related pathophysiology 
in AD. 
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INTRODUCTION 
Alzheimer's disease (AD) is the most 
prevalent form of dementia and is an age-re-
lated neurodegenerative disorder leading to 
loss of memory and learning dysfunction in 
mid to late life (Sadigh-Eteghad et al., 2014a). 
AD is characterised by an inexorable loss of 
neurons, particularly in the hippocampus and 
cerebral cortex resulting in cognitive dysfunc-
tion. From the histopathological point of 
view, AD progression is most commonly as-
sociated with extracellular deposition of beta-
amyloid (Aβ) peptides in the brain which 
forms senile plaques (SPs) and tau protein 
which creates neurofibrillary tangles (NFT) 
(Sadigh-Eteghad et al., 2014b; Serrano-Pozo 
et al., 2011).  
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Most experts agree that AD develops as a 
result of numerous factors rather than a single 
cause which exert their effects nearly twenty 
years before AD symptoms appear. The “am-
yloid cascade” hypothesis is the most com-
mon and accepted theory and proposes that 
assembly of Aβ and toxic effects of its oligo-
meric forms cause AD, while other patholog-
ical changes are downstream to the continuing 
aggregation of Aβ (Correia et al., 2011). Also, 
alteration in Aβ regulatory factors such as am-
yloid precursor protein (APP), beta-site APP-
cleaving enzyme 1 (BACE1), presenilin (PS) 
1 or 2, apolipoprotein E (APOE), neprilysin 
(NEP) and insulin-degrading enzyme (IDE), 
could play an important role in AD initiation 
and progression (Dong et al., 2012). 
Prevention in the earliest stages of AD is 
probably the most effective way to reduce the 
prevalence of this disorder (Riedel, 2014). 
This could define interventional trials in AD 
and draw particular attention to AD-prevent-
ing activities (Vellas et al., 2011). Moreover, 
international efforts have aimed to develop 
preventive strategies due to the lack of dis-
ease-modifying therapies (Ahlskog et al., 
2011). 
There are some preventable lifestyle-re-
lated risk factors such as sedentary lifestyle 
and lack of physical activity which increase 
the risk of dementia and AD (Sink et al., 2015; 
Prakash et al., 2014). A rapidly growing body 
of evidence strongly suggests that physical 
exercise may attenuate cognitive impairment 
and reduce the risk of AD via a variety of 
mechanisms (Ahlskog et al., 2011). However, 
these findings are not universal and some 
studies could not prove this association (Sink 
et al., 2015) (Table 1). Evidence suggests that 
physical activity may attenuate cognitive im-
pairment through Aβ-independent mecha-
nisms such as a decrease in the activated mi-
croglia and increase in the brain-derived neu-
rotrophic factor (BDNF) positive cells (Xiong 
et al., 2015). However, Aβ is one of the most 
important role players in AD pathology and 
prevention (Sadigh-Eteghad et al., 2014b). It 
seems that exercise improves learning and 
memory, increases hippocampal neurogene-
sis, plasticity as well as volume, and de-
creases Aβ load and plaque deposition in the 
central nervous system (CNS) (Hötting and 
Röder, 2013). Therefore, this study aims to 
gather and review the old and most recent data 
on the role of physical activity in Aβ-related 
pathophysiology of AD.  
 
BETA-AMYLOID  
One of the theories explaining the pathol-
ogy of AD is "amyloid cascade hypothesis" 
that was first purposed in 1992 (Hardy and 
Higgins, 1992). According to this popular the-
ory, the primary pathological event in AD in-
cludes Aβ peptide production and deposition 
in the brain parenchyma, which leads to the 
formation of SPs, NFTs, death of neurons, 
and eventually dementia (Armstrong, 2011; 
Karran et al., 2011). 
Aβ peptide can be detected in human cer-
ebrospinal fluid (CSF) in various forms in-
cluding Aβ40 and Aβ42. The latter is the most 
common type and is more toxic than the for-
mer (Giedraitis et al., 2007; Yan and Wang, 
2006). Hence, in most familial AD cases, 
Aβ42/Aβ40 ratio is elevated in the brain which 
predisposes individuals to AD (Karran et al., 
2011; Kumar‐Singh et al., 2006). Alterna-
tively, the active and likely the most toxic 
Aβ species are the soluble oligomers which 
form fibrils as the main component of Aβ 
plaques (Jagust and Mormino, 2011). 
It has been found that exercise exerts its 
anti-Aβ effects through various mechanisms.  
Evidence suggests that exercise decreases sol-
uble Aβ42 protein in AD mice brain (Zhao et 
al., 2015). Physical activity also significantly 
decreases soluble Aβ40 and fibrillar Aβ in the 
aged transgenic AD mice (Nichol et al., 
2008). Similarly, a randomised controlled 
trial showed that high-intensity aerobic exer-
cise in patients with MCI decreases plasma 
concentrations of Aβ42 (Baker et al., 2010). 
Further, studies using transgenic AD mice 
have shown that exercise causes a reduction 
in Aβ load and APP metabolism in brain (Cho 
et al., 2010; Leem et al., 2009; Um et al., 2008).
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Table 1: Effects of physical activity on cognition and related mechanisms in clinical and experimental studies. AD, Alzheimer’s disease; MCI, mild cognitive 
impairment; CBF, cerebral blood flow; BOLD, blood-oxygen-level-dependent; BACE-1, β-site amyloid precursor protein cleaving enzyme 1; PSD95, postsynaptic 
density protein 95; SOD, superoxide dismutase; MDA, malondialdehyde; Aβ, beta-amyloid; BDNF, brain-derived neurotrophic factor; IL, interleukin; TNF-α, 
tumour necrosis factor-α; MMP9, matrix metallopeptidase 9; LRP1, lipoprotein receptor-related protein 1; HSP70, heat shock protein 70; IDE, insulin degrading 
enzyme; HFD, high-fat diet. 
Species Health/ 
illness 
condition 
Physical  
activity 
Duration Effects on cognition Mechanism Reference 
Human MCI Light and vig-
orous 
Midlife (Dura-
tion not men-
tioned) 
Lowering risk of MCI inci-
dent 
Not assessed (Krell‐Roesch et 
al., 2016) 
Human Healthy 
elders and 
MCI 
Moderate-in-
tensity walking 
12-week Protection against future 
cognitive decline 
Increases cortical thickness (Reiter et al., 
2015) 
Human Healthy 
elders 
Moderate in-
tensity physi-
cal activity 
24-month No significant effect Not assessed (Sink et al., 
2015) 
Human MCI Combined 
physical/cog-
nitive activity 
7-month Improvement cognitive 
status and indicators of 
brain health 
Increase in  para-hippocampal CBF 
and BOLD activity 
(Train the Brain 
Consortium, 
2017) 
Human MCI High-intensity 
aerobic exer-
cise 
6-month Improvement executive 
control processes 
Glucometabolic and hypothalamic-pi-
tuitary-adrenal axis modulation 
(Tapia‐Rojas et 
al., 2016) 
Human AD and 
Dementia 
Leisure-time 
physical activ-
ity 
Twice a week 
in midlife (Du-
ration not men-
tioned) 
Decrease in risk of de-
mentia and AD 
Not assessed (Prakash et al., 
2014) 
Human APOE4 
carrier 
Moderate to 
vigorous inten-
sity physical 
activity 
Three or more 
days per week 
(Duration not 
mentioned) 
Decrease in risk of de-
mentia in cognitively in-
tact but genetically at-risk 
elders 
Increase in memory-related brain ac-
tivation 
(Deeny et al., 
2012) 
Human APOE4 
carrier 
Moderate to 
vigorous inten-
sity physical 
activity 
Three or more 
days per week 
(Duration not 
mentioned) 
Decrease in risk of de-
mentia in individuals at in-
creased genetic risk for 
AD 
Preservation of hippocampal volume (Raichlen and 
Alexander, 2014) 
Rat Aging Treadmill ex-
ercise 
8-week Improvement of learning 
and memory performance 
Down-regulation of BACE-1- Increase 
in the SOD activity and decrease in 
MDA content 
(Liu et al., 2013) 
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Species Health/ 
illness 
condition 
Physical  
activity 
Duration Effects on cognition Mechanism Reference 
NSE/htau23 mice AD Treadmill ex-
ercise 
3-month Not assessed Decrease in the p-tau level in brain 
and increase in the SOD level 
(Um et al., 2008) 
CRND8 mice AD Voluntary 
wheel running 
5-month Enhancement of the rate 
of spatial learning 
Decrease in the extracellular Aβ 
plaques and proteolytic fragments of 
APP 
(Cho et al., 
2010) 
APP/PS1 mice AD Treadmill ex-
ercise 
9-week Increase in the hippocam-
pus-associated memory 
and also restoration of 
the amygdala-associated 
memory 
Increase in the levels of p-TrkB, p-
AKT and p-PKC - Reduction of the 
levels of soluble Aβ in the amygdala 
and hippocampus 
(Nichol et al., 
2008) 
 
APPswe/PS1∆E9 
mice 
AD Voluntary 
wheel running 
10-week Prevention of spatial 
memory loss 
Decrease in the Aβ oligomers  and p-
tau – Increase in the neurogenesis in 
the hippocampus 
(Herring et al., 
2011) 
APPswe/PS1dE9 
mice 
AD Treadmill ex-
ercise 
5-month Improvement of spatial 
memory 
Increase in the BDNF-positive cells - 
Decrease in the activated microglia 
(Xiong et al., 
2015) 
3xTg-mice AD Treadmill ex-
ercise 
12-week Reversing cognitive de-
cline 
Decrease in the Aβ and p-tau levels - 
Modulation of PSD-95, synaptophy-
sin and BDNF levels 
(McConlogue et 
al., 2007) 
PS2 mutant mice AD Treadmill ex-
ercise 
12-week Improvement of spatial 
learning and memory 
Reduction of Aβ42 through the inhibi-
tion of BACE-1 - Down-regulates 
caspase-12, caspase-3, BAX - Re-
duces TNF-α, IL-1α levels and  
TUNEL positive cells 
(Cho et al., 
2015) 
APP/PS1 mice AD Treadmill ex-
ercise 
5-month Improvement of cognition Reduction of Aβ deposition and tau 
phosphorylation – Inhibition of  activ-
ity of GSK3 
(Kang et al., 
2013) 
APP/PS1 mice AD Treadmill ex-
ercise 
5-month Prevention of impairment 
of spatial learning and 
memory 
Improvement in the synaptic plasticity 
and reduction of soluble Aβ levels 
(Zhao et al., 
2015) 
Tg2576 mice AD Voluntary 
wheel running 
3-week Improvement of cognitive 
performance 
Decrease in the  soluble Aβ40 and sol-
uble fibrillar Aβ and pro-inflammatory 
markers like IL-1β and TNF-α 
(Diegues et al., 
2014) 
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Species Health/ 
illness 
condition 
Physical  
activity 
Duration Effects on cognition Mechanism Reference 
NSE/APPsw mice AD Treadmill ex-
ercise 
16-week Improvement of cognitive 
dysfunction 
Decrease in Aß42, cytochrome C, 
caspase-9, caspase-3 and Bax – In-
crease in BDNF, SOD-1, catalase 
and Bcl-2 
(Nichol et al., 
2008) 
Tg2576 mice AD Treadmill ex-
ercise 
3-month Not assessed Decrease insoluble Aβ40 and Aβ42 – 
Elevation of neprilysin, IDE, MMP9, 
LRP1 and HSP70 levels 
(Zhao et al., 
2007) 
APP mice AD and 
HFD 
Voluntary 
wheel running 
10-week Amelioration of HFD-in-
duced memory deficit 
Reduction of Aβ deposition and 
strengthening the activity of neprilysin 
(Kim et al., 2011) 
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Physical activity also results in a reduction in 
extracellular Aβ which appears to be medi-
ated by a change in the processing of APP 
(Adlard et al., 2005). Besides, preventive 
physical stimulation before disease onset al-
ters APP processing and increases Aβ degra-
dation (Herring et al., 2011). Additionally, 
Aβ-dependent neuronal cell death in the hip-
pocampus of transgenic AD mice markedly 
decreases following exercise suggesting the 
inhibitory potential of exercise in both Aβ42 
and neuronal death pathways. Furthermore, 
exercise is known to enhance hippocampus-
associated memory and amygdala-associated 
neuronal function and serve as a mean to de-
lay the onset of AD in transgenic mice (Lin et 
al., 2015). It was recently reported that volun-
tary wheel running decreases astrogliosis and 
increases neurogenesis in the hippocampus of 
runner AD mice (Tapia‐Rojas et al., 2016).  
These results suggest that exercise repre-
sents a potential therapeutic strategy for AD 
by reducing beta-amyloidogenesis and brain 
beta-amyloid burden (Um et al., 2008).  
 
BETA-SITE APP CLEAVING ENZYME 1 
APP is an integral membrane glycopro-
tein that is expressed in the CNS. APP is se-
quentially cleaved by β-secretase (BACE1) 
and γ-secretase to generate Aβ (Cole and 
Vassar, 2007; Farzampour et al., 2016). In-
creased Aβ production by sequential cleavage 
of APP by β and γ-secretases contributes to 
the etiological basis of AD (Joshi and Wang, 
2015).   
BACE1 is a protease and a member of 
pepsin family with higher concentration in the 
neurons which cleaves APP at β-site and in-
creases Aβ level in neurons (Yan and Vassar, 
2014). BACE1 concentration is roughly two-
fold higher in the brain of AD patients com-
pared with a healthy non-demented brain 
(Yan and Vassar, 2014). Also, BACE1 inhib-
itors can decrease Aβ production in neurons 
(McConlogue et al., 2007).  
It has been shown that BACE1 expression 
diminished in triple transgenic mice follow-
ing a treadmill running protocol (Cho et al., 
2015). Also, there is evidence that, treadmill 
exercise may modulate APP processing 
through BACE1 suppression and decrease Aβ 
generation and deposition in neurons (Kang et 
al., 2013; Liu et al., 2013). Furthermore, it 
was shown that treadmill exercise signifi-
cantly improves learning and memory perfor-
mance in d-galactose-induced ageing in rats 
by repression of Aβ42 protein levels, through 
down-regulation of BACE1 mRNA in the rat 
hippocampus (Yu et al., 2013). Finally, exer-
cise can reduce BACE1 content which is ac-
companied by a reduction in Akt, ERK, and 
signalling in the cortex, indicating a decline in 
cellular stress (MacPherson et al., 2015). 
 
PRESENILIN 1/2  
AD can also result from autosomal domi-
nant mutations in PS1 and PS2, both of which 
are homologous proteins. PS1 is part of the γ-
secretase complex that processes APP, but 
PS2 attaches to the complex and helps to 
stabilise it (Kang et al., 2013; Karran et al., 
2011; Zhang et al., 2013). Autosomal domi-
nant mutations in PS1 or PS2 change APP 
processing towards Aβ42 (Hardy and Selkoe, 
2002; Scheuner et al., 1996). It is now broadly 
recognised that γ-secretase constitutes at least 
four different proteins: PS1, PS2, nicastrin, 
and Aph-1 (Edbauer et al., 2003) where PS is 
the catalytic core of the complex (De 
Strooper, 2003). Mutations in PS1/2 mainly 
account for early onset familial AD (Larner 
and Doran, 2006). Many of these mutations 
enhance the relative aggregation of more neu-
rotoxic Aβ42 peptides (Hardy and Selkoe, 
2002). 
It has been proved that exercise inhibits 
PS2 mutation-induced memory impairment 
and activation of β-secretase, and reduces 
Aβ42 depositions in the cortex and hippocam-
pus of aged PS2 mutant mice (Kang et al., 
2013). Consistently, physical activity signifi-
cantly reduces the PS1 expression and APP 
phosphorylation in the hippocampus of 
APP/PS1 mice which is accompanied by a re-
markable decrease in the aggregation of Aβ 
(Liu et al., 2013). 
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APOLIPOPROTEIN E  
APOE is a class of apolipoprotein pre-
dominantly found in CNS and is normally 
synthesised and produced by astrocytes and 
microglia, but neuropathologically by 
neurons (Grehan et al., 2001; Leoni et al., 
2010; Mahley, 2016; Xu et al., 2000). There 
are three common APOE alleles in human: 
APOE2, APOE3 and APOE4. While trans-
porting cholesterol is a primary function, 
APOE also regulates Aβ metabolism 
(Kanekiyo et al., 2014). APOE protein exists 
in senile plaques and can bind to the hydro-
phobic Aβ peptides (Strittmatter et al., 1993) 
and affects the formation, agreeability, or 
clearance of extracellular Aβ (Honjo et al., 
2012).  
Alterations in lipid homoeostasis could 
serve as common denominator for APOE and 
Aβ dysfunctions in AD (Poirier, 2000). 
Further, series of experiments demonstrate 
that cognate proteins which mediate the clear-
ance of Aβ with APOE2, APOE3 and APOE4 
become increasingly less effective at clearing 
Aβ (Karran et al., 2011). Among these three 
human APOE isoforms, APOE4 increases the 
risk of AD. Heterozygous APOE-ε4 carriers 
(ε2/ε4 or ε3/ε4) have 3-4 times higher risk of 
developing AD (Honjo et al., 2012; Jagust 
and Mormino, 2011; Mahley et al., 2006). It 
has been shown that APOE-ε4 allele highly 
involves in the Aβ deposition and is an im-
portant genetic cause for late-onset AD (Ba et 
al., 2016; Schmechel et al., 1993; Rebeck et 
al., 1993). Alternatively, APOE4 can change 
Aβ40 into an Aβ42-like structure or more ag-
gregated APOE4-Aβ40 complex (Kim et al., 
2009).  
Recently, studies have revealed a novel 
interaction between APOE status and exercise 
engagement (Head et al., 2012; Low et al., 
2010; Prakash et al., 2014; Smith et al., 2016). 
It has been shown that regular physical activ-
ity may prevent or delay symptoms of demen-
tia and AD, especially among persons with 
APOE ε4 allele (Rovio et al., 2005). Schuit et 
al. found that the risk of cognitive decline was 
higher in participants who reported less than 
1 hour of physical activity daily and were also 
APOE4 carriers (Schuit et al., 2001). It is in-
dicated that amyloid levels were higher in the 
brain of physically inactive APOEε4 allele 
carriers but were lower in physically active ε4 
carriers that were tantamount to those of non-
carriers (Head et al., 2012). Similarly, other 
neuroimaging studies have reported that 
physical activity could be more effective in ε4 
carriers than in non-carriers (Deeny et al., 
2012; Smith et al., 2011).  Also, there is an 
inverse association between dementia risk 
and physical activity in APOE4 non-carriers 
which is lower than APOE4 carriers (Luck et 
al., 2014; Podewils et al., 2005; Rovio et al., 
2005).  
Besides Aβ-dependent pathways, physi-
cal activity can improve cognitive function in 
adult ε4 carriers through other mechanisms 
such as improved perfusion and neurogenesis 
as well as neuroprotective processes 
(Raichlen and Alexander, 2014).  
Smith et al. suggested that APOE geno-
type knowledge can play an essential role in 
providing recommendations on physical ac-
tivity for elderly as a tool to prevent future 
cognitive decline and brain atrophy (Smith et 
al., 2014). In general, these results propose 
that people who are genetically more suscep-
tible to AD benefit profoundly more from ef-
fects of physical activity. 
 
NEPRILYSIN/INSULIN-DEGRADING 
ENZYME  
Neprilysin (NEP) and insulin degrading 
enzyme (IDE) are part of degrading enzymes, 
which determine Aß concentration (Miners et 
al., 2008). Due to age-related genetic muta-
tion, the activity of these enzymes decreases 
which predisposes the patient to AD (Eckman 
and Eckman, 2005; Marr et al., 2004). Over-
all, growing evidence suggests that NEP and 
IDE levels decrease in AD leading to the dis-
ruption of the balance between production 
and clearance of Aβ in AD (Dong et al., 
2012). 
NEP, known as a thermolysin-like zinc 
metallopeptidase, is a type-II integral mem-
brane protein mostly found in kidney (El-
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Amouri et al., 2008; Gayathiri et al., 2014). 
This enzyme is located pre and postsynapt-
ically in neuronal cells and is able to cleave 
monomeric and oligomeric forms of Aβ from 
brain (El-Amouri et al., 2008; Miners et al., 
2006). Overexpression of NEP has been 
reported to protect hippocampal neurons from 
Aβ-mediated toxicity (El-Amouri et al., 
2007).  
IDE is also a zinc metalloendopeptidase 
that is highly expressed by microglial cells 
and neurons in the brain and cleaves extra-
cellular Aβ (Miners et al., 2008; Pivovarova 
et al., 2016). In addition to its capability to 
degrade Aβ extracellularly in the brain, IDE is 
capable of removing cytoplasmic products of 
APP (Bernstein et al., 1999; Edbauer et al., 
2002; Wang et al., 2010). Some studies 
reported that IDE levels, as well as Aβ 
degradation, tend to decrease in the 
hippocampus and CSF of patients with AD 
which is more significant in APOE e4 carriers 
(Cook et al., 2003; Del Campo et al., 2015; 
Son et al., 2016). Membrane-bound IDE 
levels and its activity significantly decrease in 
MCI patients and seem to have further 
decrease during the transition from MCI to 
AD (Zhao et al., 2007).  
Moore et al. (2016) showed that NEP and 
IDE activity and mRNA expression level in-
crease in a dose-dependent manner in the cor-
tex and hippocampus by low and high-
intensity exercise training. The increase was 
higher for NEP, which is the most active Aβ 
degrading enzyme. Also, their data demon-
strated that exercise reduces extracellular sol-
uble Aβ in the brains of Tg2576 mice in a 
dose-dependent manner. Additionally, the 
swimming exercise markedly increased ex-
pression of IDE in the rat model of non-insu-
lin-dependent diabetes mellitus (Kim et al., 
2011). Voluntary exercise in high-fat-diet-
induced Aβ deposition and memory deficit in 
APP transgenic mice ameliorates Aβ deposi-
tion by strengthening the activity of NEP 
(Maesako et al., 2012). Consistently, Lazarov 
et al. (2005) observed that environmental en-
richment with running wheel significantly el-
evates the activity of NEP in the brain.  
PHYSICAL ACTIVITY AND  
COGNITIVE DECLINE IN AD/MCI  
Some factors affect physical activity im-
pact on the prevention of cognitive decline in 
AD and MCI.  
First, the timing and intensity of physical 
activity have an important effect on preven-
tion of AD and mild cognitive impairment 
(MCI). It has been shown that even light 
physical activity in mid- and late life is linked 
to a lower risk of MCI. Several mechanisms 
may be responsible for this effect including 
increased production of neurotrophic factors 
and neurogenesis, increased cerebral blood 
flow, and reduced risk of cardiovascular dis-
eases (Krell‐Roesch et al., 2016). Also, it is 
proven that moderate-intensity regular exer-
cise is associated with increased cortical 
thickness and enhanced cognitive function 
through improved cardiorespiratory fitness in 
MCI patients (Reiter et al., 2015). 
Second, the additive effects of cognitive 
training/enrichment on physical activity 
against AD and MCI have been shown in 
some studies. In a study by Sacco et al., it was 
shown that addition of cognitive tasks such as 
single reaction time and an inhibition task 
(Go-no-Go) enhances physical activity posi-
tive effects on cognitive performance in AD 
and MCI patients (Sacco et al., 2016). This 
might result from modifying effects of train-
ing tasks on blood oxygen level dependent 
(BOLD) response within task-related brain 
regions (Train the Brain Consortium, 2017). 
These factors can be used to intensify im-
proving effects of physical activity on cogni-
tive decline in dementia patients.  
 
PHYSICAL ACTIVITY AND AΒ- 
INDEPENDENT MECHANISMS 
Several studies have shown that physical 
activity can also improve cognitive function 
in AD and MCI patients through Aβ-inde-
pendent mechanisms. It has been shown that 
physical activity increases neurotrophic fac-
tors such as BDNF levels in the brain and 
through their neuroprotective effects improve 
cognition in AD (Erickson et al., 2012). Also, 
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regular physical activity acts as a precondi-
tioner against oxidative stress and reactive ox-
ygen species production (ROS). Physical ac-
tivity reduces ROS-induced protein damage 
and controls the activity of redox-sensitive 
transcription factors (Radak et al., 2007) 
which are all involved in neurodegeneration 
and dementia (Majdi et al., 2016). Physical 
activity also decreases neuroinflammation in 
the brain. In a study by Kang et al., it was 
demonstrated that treadmill exercise reduces 
neuronal cell death and TNF-α as well as IL-
1α expression levels in aged PS2 mutant mice 
and thus decreases Aβ-induced inflammatory 
response (Kang et al., 2013) that is involved 
in dementia (Majdi et al., 2016). Further, it 
has been found that endothelial function is 
impaired in patients with AD and together 
with lipid and lipoprotein metabolism may be 
part of vascular contributions to cognitive im-
pairment and dementia (VCID) (Dede et al., 
2007; Snyder et al., 2015). Physical activity 
enhances endothelial nitric oxide synthase 
(eNOS) activity in the brain vasculature, in-
creases blood flow and decreases subsequent 
cerebral damage (Endres et al., 2003).  
 
CONCLUSION 
AD progression is mostly associated with 
extracellular deposition of Aβ peptides in 
brain. Also, alteration in Aβ regulatory factors 
such as BACE1, PS1/2, NEP and IDE en-
zymes, and APOE-ε4 allele could play an 
essential role in AD progression. In addition, 
lifestyle-related risk factors such as sedentary 
life pattern and lack of physical activity in-
crease the risk of dementia and AD.  
The most effective way to protect brain 
and reduce risk of AD is likely prevention in 
preclinical stages. It seems that physical ac-
tivity especially aerobic exercise is one of 
these preventing factors. Evidence suggests 
that physical activity can improve cognitive 
function by various Aβ-dependent and inde-
pendent mechanisms including reducing 
Aβ42, APP, BACE1 and PS1 level and on the 
other hand, elevating NEP and IDE activities 
(Figure 1). Consistently, physical activity 
may reduce the risk of AD, especially among 
APOE ε4 allele carriers. Overall, physical ac-
tivity could have beneficial effects on preven-
tion or delay of symptoms of AD. Neverthe-
less, the optimum activity condition with the 
best efficacy and exact mechanisms behind 
should be clarified in future studies. 
 
Figure 1: Mechanisms of physical activity in 
prevention of Alzheimer’s disease risks 
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